Showing results (461-470 of 609) with videos related to
Sort By:
Pageof 61
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX TrialRafal Dziadziuszko, Solange Peters, Tony Mok, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2020
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2014
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibRyohei Katayama, Luc Friboulet, Sumie Koike, et al.ESMO Open|December 13, 2021
Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II studyJ J Lin, A Muzikansky, E Kennedy, et al.The Journal of Biological Chemistry|May 11, 2012
Characterization of Caulobacter crescentus FtsZ protein using dynamic light scatteringSen Hou, Stefan A Wieczorek, Tomasz S Kaminski, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2021
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIsE Felip, A T Shaw, A Bearz, et al.Lung Cancer (Auckland, N.Z.)|February 4, 2020
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 StudiesShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.JTO Clinical and Research Reports|July 11, 2022
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on CrizotinibJaime L Schneider, Alona Muzikansky, Jessica J Lin, et al.ACS Catalysis|April 15, 2026
Enantioselective Synthesis of Complex Carbocycles by C-H Insertion of Aryl/Aryl CarbenesJose M Ruiz, Dylan R Turner, Mingchun Gao, et al.Genes & Development|March 21, 2007
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesisAlice T Shaw, Alexander Meissner, James A Dowdle, et al.Pageof 61